Can genetic variations predict HCV treatment outcomes?
Selzner
Nazia
N
McGilvray
Ian
I
D000998:Antiviral Agents / Q000627:therapeutic use*; D014644:Genetic Variation / Q000235:genetics*; D005838:Genotype; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011237:Predictive Value of Tests; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a